Keros Therapeutics is a Lexington, MA–based company discovering and developing novel proprietary therapeutics for rare and ultra-rare neuromuscular diseases. Its two lead programs include a small-molecule ALK2 inhibitor program for fibrodysplasia ossificans progressiva (FOP) and a second program targeting other rare neuromuscular disorders. The ALK2 program, licensed from Massachusetts General Hospital and the NIH’s NCATS, has advanced through preclinical safety studies and was projected to enter Phase 1 SAD/MAD studies in H1 2019. Keros intends to advance both programs from preclinical validation through clinical proof-of-concept and into Phase II trials. The company recently completed a $23m Series B, bringing total venture funding to $34m to date. Leadership is headed by President and CEO Jasbir S. Seehra, and the company added Dr. Zafrira Avnur to its board as part of the financing announcement.

Total raised

$23M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2019